Vendor, Fuquay Varina, NC
Collaborations Pharmaceuticals, Inc.
UEI EFJCLL37KKH3, CAGE 7BGW7
1 award and $0 obligated between June 24, 2026 and June 24, 2026, 100% under full and open competition, against 4.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93025C00039Definitive Contract, June 24, 2026, Full and Open Competition After Exclusion of Sources, 4 offers | National Institutes of Health NiaidNational Institutes of Health | Is to Develop Pan-Influenza Inhibitors Targeting the PA Endonuclease from the Viral Replication Complex by Demonstrating Pyronaridine as a VNAICS 541714, PSC AN12 | $0 |
- Places of performance
- North Carolina
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 1 across 1 awards